FCI

Executive Summary

FCI is a privately held medical device company specializing in ophthalmic surgical products, particularly for lacrimal (tear duct) surgery, dry eye, cataract, eyelid repair, orbital implants, and vitreoretinal procedures. Founded in 1988 and headquartered in Marshfield, United States, the company has built a comprehensive portfolio of minimally invasive, preloaded, and self-retaining devices that simplify surgical techniques and improve patient outcomes. FCI's products are widely used by ophthalmologists globally, and the company holds a strong position in the niche lacrimal surgery market, where it offers a range of stents, tubes, and intubation sets. The company's stage is 'Approved,' indicating that it has received regulatory clearances and is actively commercializing its devices. As a mature player in the ophthalmic device space, FCI benefits from the growing prevalence of dry eye disease and increasing adoption of minimally invasive procedures. However, being private, the company lacks public financial disclosures, making it difficult to assess its growth trajectory. FCI faces competition from larger medical device firms like Alcon and Bausch + Lomb, but its specialized focus on lacrimal and anterior segment surgery provides a defensible niche. The company's future growth likely hinges on expanding its product line, entering new geographic markets, and leveraging clinical data to support adoption. Overall, FCI appears to be a stable but low-growth entity in a specialized segment, with moderate upside from product innovation and market expansion.

Upcoming Catalysts (preview)

• H2 2026FDA Clearance for Next-Generation Lacrimal Stent60% success
• 2026Distribution Partnership for Asia-Pacific Expansion70% success
• Q1 2027Publication of Pivotal Study Results for Dry Eye Device50% success